Beijing Synthetic Vaccine Biosciences Co. Ltd. has synthesized Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of autoimmune disease, cancer, inflammatory disorders and viral infection.
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute and chronic pain.
Canwell Biotech Ltd. has described antibody-drug conjugates (ADCs) comprising an antibody covalently linked to a Toll-like receptor 7 (TLR7) and TLR8 agonist through a cleavable or noncleavable linker reported to be useful for the treatment of cancer, allergy, autoimmune diseases, immunodeficiency disorder, sepsis and infections.
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, type 2 diabetes, diabetic nephropathy, dyslipidemia and obesity.
Institute of Cancer Research UK has identified proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau disease tumor suppressor (VHL) binding moiety coupled to a receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) targeting moiety via a linker.
Hainan Simcere Pharmaceutical Co. Ltd. has synthesized protein degradation inducers comprising a regulator and/or promoter of protein proteasomal degradation moiety covalently linked to a protein targeting moiety through a linker reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has disclosed protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Glenmark Pharmaceuticals Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) targeting moiety via linker reported to be useful for the treatment of cancer.
RSS